(186)Re-epratuzumab

N/A

Report date: 2025/10/20 14:38:41

Base Information

Drug Name(186)Re-epratuzumab

Drug Alias Name186Re-epratuzumab

ClassificationRadiation-emitting products > Nuclides > Rhenium > 186ReRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-CD22

TargetsCD22

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Medical Center Nijmegen

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center Nijmegen

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A